A Phase 2 interventional study of ALX-0171 1.5 mg/kg and Placebo in Respiratory Syncytial Virus Lower Respiratory Tract Infection, sponsored by Ablynx, a Sanofi company. Terminated at 25 sites in Japan. Open to participants aged 28 Days to 2 Years. Per ClinicalTrials.gov, last updated 2019-07-30.
Sponsored by Ablynx, a Sanofi company (part of Sanofi) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This was a randomized, double-blind, multicenter, Phase II study (NCT03418571) designed to support the selection of an optimal dose of inhaled ALX-0171 for further clinical development, taking ethnicity into consideration.
Based on the results of the Phase IIb dose-ranging study ALX0171-C201 (RESPIRE), the Sponsor decided to discontinue ALX-0171 development in infants and to early terminate the ALX0171-C203 study.
Four dose levels were planned to be evaluated in four consecutive cohorts consisting of Japanese infants and young children aged 28 days to \<2 years with a gestational age ≥33 weeks who were hospitalized for and diagnosed with respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI):
Each cohort was planned to consist of 15 subjects enrolled and randomly assigned to receive ALX-0171 or placebo, in an allocation ratio of 4:1 (N = 12 active versus N = 3 placebo per cohort).
Due to early termination of the trial, only enrollment of Cohort 1 could be completed as planned. For Cohort 2, only 1 subject was screened but did not meet the eligibility criteria and was considered a screen failure. Therefore, data were not available for treatment groups ALX-0171 3.0 mg/kg, 6.0 mg/kg, and 9.0 mg/kg.
Of note, in line with applicable guidelines, an Independent Data Monitoring Committee (IDMC) was assigned to monitor the study. Upon completing of Cohort 1, the IDMC reviewed the available unblinded safety data and unanimously recommended to continue the study with no changes to the protocol.
Ablynx, a Sanofi company is the lead sponsor of 25 studies on the registry; none are open to participants now.
First submitted before Ablynx became part of Sanofi.
Counted across the registry records on this site, refreshed daily.
Main inclusion criteria:
Subject fulfilled at least two of the following RSV disease severity criteria at screening and randomization:
Inadequate oxygen saturation defined as:
Signs of respiratory distress defined as:
Others as defined in the protocol
Main exclusion criteria:
Subject was known to have significant comorbidities including:
Subject was critically ill and/or was expected to require invasive mechanical ventilation, non-invasive respiratory support (i.e., continuous or bilevel positive airway pressure), or high-flow oxygen therapy (HFOT) at levels not enabling nebulization therapy according to the Investigator's judgment. High-flow oxygen, with a maximum flow of 2 L/kg/min, was permitted under the following conditions:
Others as defined in the protocol
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: ALX-0171 1.5 mg/kg
Other: Placebo
Drug page: Gontivimab
ALX-0171 1.5 mg/kg was administered via a single inhalation once daily for 3 consecutive days.
Placebo was administered via a single inhalation once daily for 3 consecutive days.
Safety and Tolerability of Inhaled ALX-0171 1.5 mg/kg as Measured by the Number of Subjects With at Least 1 Serious or Non-Serious Treatment-emergent Adverse Event (TEAE).
Number of subjects reported with at least 1 serious or non-serious TEAEs in the ALX-0171 1.5 mg/kg treatment group and placebo treatment group.
Time frame: From the subject's first study drug administration until completion of the subject's last visit, an average of 4 weeks
Safety and Tolerability of Inhaled ALX-0171 1.5 mg/kg as Measured by the Number of Serious and Non-serious TEAEs.
Number of serious and non-serious TEAEs reported in the ALX-0171 1.5 mg/kg treatment group and placebo treatment group.
Time frame: From the subject's first study drug administration until completion of the subject's last visit, an average of 4 weeks
Sixteen subjects were screened for Cohort 1. Of these, 15 subjects were randomized. There was 1 screen failure due to consent withdrawal. For Cohort 2, 1 subject was screened but considered a screen failure (consent withdrawal). Consent was obtained from the first subject on 1 March 2018; last subject completed the final visit on 19 October 2018
| Milestone | ALX-0171 1.5 mg/kg | Placebo |
|---|---|---|
| Started | 12 | 3 |
| Completed | 11 | 3 |
| Not completed | 1 | 0 |
| Withdrew: Consent withdrawn by legal guardian | 1 | 0 |
Number of subjects reported with at least 1 serious or non-serious TEAEs in the ALX-0171 1.5 mg/kg treatment group and placebo treatment group.
| participants | ALX-0171 1.5 mg/kg | Placebo |
|---|---|---|
| At least one serious TEAE | 1 | 0 |
| At least one non-serious TEAE | 8 | 1 |
Number of serious and non-serious TEAEs reported in the ALX-0171 1.5 mg/kg treatment group and placebo treatment group.
| TEAE | ALX-0171 1.5 mg/kg | Placebo |
|---|---|---|
| Serious TEAE | 2 | 0 |
| Non-Serious TEAE | 18 | 1 |
Collected over From the subject's first study drug administration until the subject's study completion/discontinuation date, an average of 4 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ALX-0171 1.5 mg/kg | 0/12 (0%) | 1/12 (8.3%) | 8/12 (66.7%) |
| Placebo | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| Event | ALX-0171 1.5 mg/kg | Placebo |
|---|---|---|
| Pneumonia hemophilusInfections and infestations | 1/12 | 0/3 |
| Pneumonia bacterialInfections and infestations | 1/12 | 0/3 |
| Event | ALX-0171 1.5 mg/kg | Placebo |
|---|---|---|
| Hepatic function abnormalHepatobiliary disorders | 0/12 | 1/3 |
| MiliariaSkin and subcutaneous tissue disorders | 3/12 | 0/3 |
| Upper respiratory tract infectionInfections and infestations | 2/12 | 0/3 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 1/12 | 0/3 |
| Dermatitis diaperSkin and subcutaneous tissue disorders | 1/12 | 0/3 |
| ErythemaSkin and subcutaneous tissue disorders | 1/12 | 0/3 |
| Otitis mediaInfections and infestations | 1/12 | 0/3 |
| Otitis media acuteInfections and infestations | 1/12 | 0/3 |
| Pneumonia bacterialInfections and infestations | 1/12 | 0/3 |
| DiarrhoeaGastrointestinal disorders | 1/12 | 0/3 |
| Age, Continuous(months) | ALX-0171 1.5 mg/kg | Placebo | Total |
|---|---|---|---|
| Mean | 7.4 ± 4.65 | 3.5 ± 3.04 | 6.6 ± 4.58 |
| Sex: Female, Male(Participants) | ALX-0171 1.5 mg/kg | Placebo | Total |
|---|---|---|---|
| Female | 5 | 2 | 7 |
| Male | 7 | 1 | 8 |
| Race (NIH/OMB)(Participants) | ALX-0171 1.5 mg/kg | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 12 | 3 | 15 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2018 to primary completion in Oct 2018, 7 months.
Results were first posted in Jul 2019, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gontivimab